Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-12-19
2006-12-19
Haddad, Maher M. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S143100
Reexamination Certificate
active
07150871
ABSTRACT:
Methods and compositions comprising antagonists of αvβ6 are provided for the treatment of acute lung injury fibrosis.
REFERENCES:
patent: 5514788 (1996-05-01), Bennett et al.
patent: 5654270 (1997-08-01), Ruoslahti et al.
patent: 5962643 (1999-10-01), Sheppard et al.
patent: 6492332 (2002-12-01), Demopulos et al.
patent: WO 90/06767 (1990-06-01), None
B.A. Imhof et al. Current Top Microbiol Immunol. 1996; 213 (Pt1): 195-203.
A Weinackeret al. J Biol Chem, 1994; 269(9): 6940-6948.
G Dermer. Biotechnology 12, Mar. 1994.
M Osband et al. Immunol Today 11(6): 193-195, 1990.
E Harlow et al. Antibodies Cold Spring Harbor, 1988.
R Fenton et al. J NCI 87(4), 1995.
A. Mountain. TibTech 18: 119127, 2000.
Marshall et al. Comparative analysis of integrins in vitro and in vivo in uveal and cutaneous melanomas. Br J Cancer. Feb. 1998;77(4):522-9.
Weiner LM. An overview of monoclonal antibody therapy of cancer. Semin Oncol. Aug. 1999;26(4 Suppl 12):41-50.
Breuss et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci. Jun. 1995;108 ( Pt 6):2241-51.
Dillman RO.Monoclonal antibodies for treating cancer. Ann Intern Med. Oct. 1, 1989;111(7):592-603.
Agrez, M., et al. “The αvβ6 Integrin Promotes Proliferation of Colon Carcinoma Cells through a Unique Region of the β6 Cytoplasmic Domain,”The Rockefeller University Pres., vol. 127, No. 2, pp. 547-556 (Oct. 1994).
Agrez, M., et al. “Integrin αvβ6 Enhances Coxsackievirus B1 Lytic Infection of Human Colon Cancer Cells,”Virology239, 71-77 (1997).
Berkow, R., M.D., et al. “The Merck Manual of Diagnosis and Therapy,”Merck Professional Handbookspp. 642-646 16th Editon, 1992.
Cheresh, et al., “A Novel Vitronectin Receptor Integrin (αvβx) Is Responsible for Distinct Adhesive Properties of Carcinoma Cells,”Cell, vol. 57, 59-69 (Apr. 7, 1989).
Edgington, Stephen M., “How Sweet It Is: Selectin-Mediating Drugs,”Biotechnology, 10:383-389 (1992).
Griffiths, M., et al., “Inactivation of the β6 Integrin Subunit Gene Protects Against Bleomycin-Induced Pulmonary Fibrosis,” Molecular Biology of the Cell, Bethesda, MD vol. 7, p. 166A (1996).
Freed, E. et al., “A novel integrin β subunit is associated with the vitronectin receptor α subunit (αv) in a human osteosarcoma cell line and is a substrate for protein kinase C,”The EMBO Journal, vol. 8, No. 10, pp. 2955-2965 (1989).
Holzmann, B., et al., “Identification of a Murine Peyer's Patch-Specific Lymphocyte Homing Receptor as an Integrin Molecule with an α Chain Homologous to Human VLA-4α,”Cell, 56:37-46 (Jan. 13, 1989).
Huang, X., et al., “Inactivation of the Integrin β6 Subunit Gene Reveals a Role of Epithelial Integrins in Regulating Inflammation in the Lungs and Skin,”The Journal of Cell Biology, 133:4, Plaintiff. 921-928 (May 1996).
Huang, X., et al., “Expression of the Human Integrin β6 Subunit in Alveolar Type II Cells and Bronchiolar Epithelial Cells Reverses Lung Inflammation in β6 Knockout Mice,”Am. J. Respir. Cell Mol.. Biol., 19:636-642 (1998).
Hynes, R.O., et al., “Contact and Adhesive Specificities in the Associations, Migrations, and Targeting of Cells and Axons,”Cell, 68:303-322 (1992).
Kajiji et al., “A novel integrin (αEβ4) from human epithelial cells suggests a fourth family of integrin adhesion receptors,”The EMBO Journal, 8:673-680 (1989).
Kogan et al., “A Single Amino Acid Residue Can Determine the Ligand Specificity of E-selectin,”The Journal of Biological Chemistry, vol. 270 No. 23 :14047-14055 (1995).
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,”The Protein Folding Problem and Tertiary Structure Prediction, K. Merz, Jr. and S. LeGrand, Editors, Birkhauser Boston 1994 pp. 491-495.
Ramaswamy et al., “Cloning, primary structure and properties of a novel human integrin β subunit,”The EMBO Journal, vol. 9, No. 5 pp. 1561-1568 (1990).
Rozdzinski et al., “Antiinflammatory Effects in Experimental Meningitis of Prokaryotic Peptides that Mimic Selectins,”The Journal of Infectious Diseases, 168:1422-8 (1993).
Ruoslahti et al., “New Perspectives in Cell Adhesion: RGD and Integrins,”Sciencevol. 238 pp. 491-497 (Oct. 23, 1987).
Sheppard et al., “Complete Amino Acid Sequence of a Novel Integrin β Subunit (β6) Identified in Epithelial Cells Using the Polymerase Chain Reaction,”The Journal of Biological Chemistry, vol. 265 No. 20 pp. 11502-11507 (1990).
Sheppard et al., “Use of Homology PCR To Identify A Novel Integrin Beta Chain From Airway Epithelium,”Am Rev. Respir. Dis, 141:A707 (1990).
Ward et al., “Blocking of adhesion molecules in vivo as anti-flammatory therapy,”Therapeutic Immunology, 1:165-171 (1994).
Weinacker et al., “Role of the Integrin αvβ6 in Cell Attachment to Fibronectin,”The Journal of Biological Chemistry, vol. 269 No. 9 pp. 6940-6948 (1994).
Yokosaki et al., “Differential Effects of the Integrins α9β1, αvβ3, and αvβ6 on Cell Proliferative Responses to Tenascin,”The Journal of Biological Chemistry, vol. 271 No. 39 pp. 24144-24150 (1996).
Vaderslice, et al., “A Cyclic Hexapeptide is a Potent Antagonist of α4Integrins”;The Journal of Immunology158: 1710-1718 (1997).
JPA van Pelt, et al., “The Regulation of CD11b Integrin Levels on Human Blood Leukocytes and Leukotriene B4-Stimulated Skin by a Specific Leukotriene B4 Receptor Antagonist (LY293111)”;Biochemical Pharmacologyvol. 53, pp. 1005-1012 (1997).
McIntyre, et al., “Regulation of Human T Lymphocyte Coactivation with an α4Integrin Anatagonist Peptide”;The Journal of Immunology158: 4180-4186 (1997).
Engleman, et al., “A Peptidomimetic Antagonist of the αvβ3Integrin Inhibits Bone Resorption In Vitro and Prevents Osteoporosis In Vivo”;J. Clin. Invest., vol. 99, No. 9 (May 1997).
Kapil, et al., “Biological Matrix-Dependent Pharmacokinetic and Pharmacodynamic Parameters of a Novel Platelet Glycoprotein IIB/IIIA Receptor Antagonist, XU063, In Beagle Dogs”;Thrombosis Research, vol. 86, No. 3, pp. 221-232 (1997).
Craig, et al., “Concept and Progress in the Development of RGD-Containing Peptide Pharmaceuticals”;Biopolymers(Peptide Science), vol. 37, 157-175 (1995).
“The Merck Manual of Diagnosis and Therapy”;Merck Professional Handbooks, Sixteenth Edition (1992) pp. 642-646.
Breuss, J. M. et al., “Expression of the β6 Integrin Subunit in Development, Neoplasia and Tissue Repair Suggests a Role in Epithelial Remodeling”;Journal of Cell Science, 108:2241-2251 (1995).
Lehmann, M. et al., “A Monoclonal Antibody Inhibits Adhesion to Fibronectin and Vitronectin of a Colon Carcinoma Cell Line and Recognizes the Integrins”;Cancer Research, 54:2102-2107 (Apr. 15, 1994).
Wang, A. et al., “Differential Regulation of Airway Epithelial Integrins by Growth Factors”;Am. J. Respir. Cell Mol. Biol., vol. 15:664-672 (1996).
Suzuki, Shintaro et al.; “Amino Acid Sequence of the Vitronectin Receptor α Subunit and Comparative Expression of Adhesion Receptor mRNAs”; 1987,The Journal of Biological Chemistry, vol. 262, No. 29, pp. 14080-14085.
Huang Xiaozhu
Sheppard Dean
Haddad Maher M.
Regents of the University of California
Townsend and Townsend / and Crew LLP
LandOfFree
Treatment of acute lung injury, fibrosis and metastasis with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of acute lung injury, fibrosis and metastasis with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of acute lung injury, fibrosis and metastasis with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3714253